Acumen reports FY2022 net loss $42.9M; Phase 1 ACU193 enrollment completed, topline Q3 2023

Acumen Pharmaceuticals, Inc.

Cash, cash equivalents and marketable securities of $193.4M as of Dec 31, 2022, expected to fund operations through 2025.
Net loss of $42.9M for FY2022 vs $100.6M in 2021 (which included $81.2M non-cash charge).
Phase 1 INTERCEPT-AD trial of ACU193 in early Alzheimer's completed enrollment Feb 2023; topline data expected Q3 2023.
Protocol amendment reduced cohort 7 dose to 25 mg/kg Q2W after blinded PK/SA, 2 asymptomatic ARIA-E cases noted.
FDA granted Fast Track designation for ACU193 in Oct 2022; Derrell Porter, M.D. joined board in Jan 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Acumen Pharmaceuticals, Inc. reported financial results for the year ended December 31, 2022.

Period: the year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 27, 2023, Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the year ended December 31, 2022.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Acumen Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001576885-23-000013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.